NCT02349607View on ClinicalTrials.gov

Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Healthy
Interventions
DRUG

PF-05089771 300mg

PF-05089771 300 mg

DRUG

PF-05089771 300 mg + pregabalin 300 mg

PF-05089771 300 mg + pregabalin 300 mg

DRUG

Placebo

Placeco

DRUG

pregabalin 300 mg

pregabalin 300 mg

DRUG

ibuprofen 600 mg

ibuprofen 600 mg

Trial Locations (1)

2333

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02349607 - Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints | Biotech Hunter | Biotech Hunter